1. Home
  2. AEF vs VNDA Comparison

AEF vs VNDA Comparison

Compare AEF & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEF

abrdn Emerging Markets Equity Income Fund Inc.

HOLD

Current Price

$7.11

Market Cap

277.7M

Sector

Finance

ML Signal

HOLD

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$8.19

Market Cap

425.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEF
VNDA
Founded
1989
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
277.7M
425.5M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
AEF
VNDA
Price
$7.11
$8.19
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$13.13
AVG Volume (30 Days)
92.5K
2.8M
Earning Date
01-01-0001
02-12-2026
Dividend Yield
7.13%
N/A
EPS Growth
N/A
N/A
EPS
0.57
N/A
Revenue
N/A
$212,074,000.00
Revenue This Year
N/A
$12.01
Revenue Next Year
N/A
$21.57
P/E Ratio
$8.86
N/A
Revenue Growth
N/A
11.12
52 Week Low
$4.40
$3.81
52 Week High
$5.53
$9.60

Technical Indicators

Market Signals
Indicator
AEF
VNDA
Relative Strength Index (RSI) 60.20 68.93
Support Level $7.00 $6.87
Resistance Level $7.23 $9.60
Average True Range (ATR) 0.11 0.49
MACD 0.02 0.13
Stochastic Oscillator 76.51 60.87

Price Performance

Historical Comparison
AEF
VNDA

About AEF abrdn Emerging Markets Equity Income Fund Inc.

ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: